

Johann K Hitzler

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7735370/publications.pdf>

Version: 2024-02-01

86
papers

2,396
citations

279798

23
h-index

214800

47
g-index

88
all docs

88
docs citations

88
times ranked

3233
citing authors

#	ARTICLE	IF	CITATIONS
1	How essential are in-person clinic visits during maintenance treatment of children with acute lymphoblastic leukemia?. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29713.	1.5	3
2	Abstract 2002: A genome-wide association study identifies novel sepsis risk loci in children with Down syndrome-associated acute lymphoblastic leukemia: A report from the Children's Oncology Group. <i>Cancer Research</i> , 2022, 82, 2002-2002.	0.9	0
3	Cognitive and behavioral risk factors for low quality of life in survivors of childhood acute lymphoblastic leukemia. <i>Pediatric Research</i> , 2021, 90, 419-426.	2.3	8
4	Treatment of acute myeloid leukemia in children: A practical perspective. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28979.	1.5	16
5	Excellent Outcomes With Reduced Frequency of Vincristine and Dexamethasone Pulses in Standard-Risk B-Lymphoblastic Leukemia: Results From Children's Oncology Group AALL0932. <i>Journal of Clinical Oncology</i> , 2021, 39, 1437-1447.	1.6	56
6	Mapping the cellular origin and early evolution of leukemia in Down syndrome. <i>Science</i> , 2021, 373, .	12.6	42
7	High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trial. <i>Blood</i> , 2021, 138, 2337-2346.	1.4	16
8	When it comes to drug access, should children be considered small adults? Countering coverage denials of FLT3 inhibitors in children with FLT3-ITD AML. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29278.	1.5	2
9	Tisagenlecleucel Therapy Is Safe and Effective for Children with Down Syndrome with ALL in First Relapse. <i>Blood</i> , 2021, 138, 4820-4820.	1.4	1
10	Blinatumomab Associated Seizure Risk in Patients with Down Syndrome and B-Lymphoblastic Leukemia: An Interim Report from Children's Oncology Group (COG) Study AALL1731. <i>Blood</i> , 2021, 138, 2304-2304.	1.4	10
11	How Important Are in-Person Clinic Visits during Maintenance Therapy for Pediatric Acute Lymphoblastic Leukemia?. <i>Blood</i> , 2021, 138, 2998-2998.	1.4	0
12	Risks of late mortality and morbidity among survivors of childhood acute leukemia with Down syndrome: A population-based cohort study. <i>Cancer</i> , 2021, , .	4.1	0
13	Targeted blockade of immune mechanisms inhibit B precursor acute lymphoblastic leukemia cell invasion of the central nervous system. <i>Cell Reports Medicine</i> , 2021, 2, 100470.	6.5	3
14	Clinical decisions following implementation of asparaginase activity monitoring in pediatric patients with acute lymphoblastic leukemia: Experience from a single-center study. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28044.	1.5	3
15	Pathologic Features of Down Syndrome Myelodysplastic Syndrome and Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML0431. <i>Archives of Pathology and Laboratory Medicine</i> , 2020, 144, 466-472.	2.5	9
16	B cell acute lymphoblastic leukemia cells mediate RANK-RANKL-dependent bone destruction. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	17
17	Quantitative MRI outcomes in child and adolescent leukemia survivors: Evidence for global alterations in gray and white matter. <i>NeuroImage: Clinical</i> , 2020, 28, 102428.	2.7	13
18	Outcomes in children with Down syndrome (DS) and B-lymphoblastic leukemia (B-ALL): A Children's Oncology Group (COG) report.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10510-10510.	1.6	7

#	ARTICLE	IF	CITATIONS
19	Outcomes with reduced intensity therapy in a low-risk subset of children with National Cancer Institute (NCI) standard-risk (SR) B-lymphoblastic leukemia (B-ALL): A report from Children's Oncology Group (COG) AALL0932.. Journal of Clinical Oncology, 2020, 38, 10509-10509.	1.6	3
20	Outcomes of Patients with Down Syndrome and CRLF2-Overexpressing Acute Lymphoblastic Leukemia (ALL): A Report from the Children's Oncology Group (COG). Blood, 2020, 136, 44-45.	1.4	1
21	A Human Model of Down Syndrome Associated Leukemia Reveals Different Cell of Origins for Initiation and Progression. Blood, 2020, 136, 11-12.	1.4	0
22	Unusual lymphoid malignancy and treatment response in two children with Down syndrome. Pediatric Blood and Cancer, 2019, 66, e27822.	1.5	1
23	Need for new thinking: Treatment of relapsed leukemia in children with Down syndrome. Pediatric Blood and Cancer, 2019, 66, e27644.	1.5	6
24	Excellent long-term survival of children with Down syndrome and standard-risk ALL: a report from the Children's Oncology Group. Blood Advances, 2019, 3, 1647-1656.	5.2	17
25	Gemtuzumab ozogamicin in acute myeloid leukemia: act 2, with perhaps more to come. Haematologica, 2019, 104, 7-9.	3.5	13
26	High-Dose Cytarabine Is Indispensable for the Survival of Children with Myeloid Leukemia of Down Syndrome Despite Negative Minimal Residual Disease Post-Induction. Blood, 2019, 134, 118-118.	1.4	3
27	Understanding Pre-Leukemia in Trisomy 21 Human HSC and Modeling Progression Towards Down Syndrome Associated Leukemia Using CRISPR/Cas9 at Single Cell Resolution. Blood, 2019, 134, 2531-2531.	1.4	1
28	Characterizing neurocognitive late effects in childhood leukemia survivors using a combination of neuropsychological and cognitive neuroscience measures. Child Neuropsychology, 2018, 24, 999-1014.	1.3	24
29	Value of flow cytometric analysis of peripheral blood samples in children diagnosed with acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2018, 65, e26738.	1.5	4
30	Brain Development and Heart Function after Systemic Single-Agent Chemotherapy in a Mouse Model of Childhood Leukemia Treatment. Clinical Cancer Research, 2018, 24, 6040-6052.	7.0	10
31	High Vs. Low-Intensity Bridging Chemotherapy in Children with Acute Lymphoblastic Leukemia Awaiting Chimeric Antigen Receptor T-Cell Therapy: A Population-Based Study from Ontario, Canada. Blood, 2018, 132, 1410-1410.	1.4	5
32	The Clonal Hematopoietic Spectrum of Down Syndrome and ML-DS. Blood, 2018, 132, 3839-3839.	1.4	2
33	Functional and Molecular Consequences of Trisomy 21 on Human Fetal Hematopoiesis. Blood, 2018, 132, 1317-1317.	1.4	0
34	Postnatally Acquired Mutations Underlie the Progression of Transient Leukemia to Myeloid Leukemia of Down Syndrome. Blood, 2018, 132, 442-442.	1.4	0
35	Inactivation of Stage-Specific B-Cell Commitment Genes Generates Distinct Molecular Subtypes of BCR-ABL1 Lymphoblastic Leukemia. Blood, 2018, 132, 569-569.	1.4	0
36	Detection of a clone-specific GATA1 mutation to monitor treatment response and involvement of a monozygotic twin in myeloid leukemia of Down syndrome. Pediatric Blood and Cancer, 2017, 64, e26439.	1.5	0

#	ARTICLE	IF	CITATIONS
37	Brain structure, working memory and response inhibition in childhood leukemia survivors. <i>Brain and Behavior</i> , 2017, 7, e00621.	2.2	41
38	Predictors of thrombohemorrhagic early death in children and adolescents with t(15;17)-positive acute promyelocytic leukemia treated with ATRA and chemotherapy. <i>Annals of Hematology</i> , 2017, 96, 1449-1456.	1.8	32
39	Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial. <i>Blood</i> , 2017, 129, 3304-3313.	1.4	71
40	Minimal Residual Disease and Childhood Leukemia: Standard of Care Recommendations From the Pediatric Oncology Group of Ontario MRD Working Group. <i>Pediatric Blood and Cancer</i> , 2016, 63, 973-982.	1.5	29
41	Clinical presentation and risk factors of serious infections in children with Down syndrome treated for acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1949-1953.	1.5	8
42	Frequency and outcome of pediatric acute lymphoblastic leukemia with <i>ZNF384</i> gene rearrangements including a novel translocation resulting in an <i>ARID1B/ZNF384</i> gene fusion. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1915-1921.	1.5	55
43	Origin of Leukemia in Children with Down Syndrome. , 2016, , 109-131.		0
44	Down Syndrome AML Is Unique in Phenotype Both at Diagnosis and in Post Chemotherapy Regeneration. <i>Blood</i> , 2016, 128, 1687-1687.	1.4	1
45	Treatment of young children with CNS-positive acute lymphoblastic leukemia without cranial radiotherapy. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1881-1885.	1.5	17
46	Neuropsychological late effects of treatment for acute leukemia in children with Down syndrome. <i>Pediatric Blood and Cancer</i> , 2015, 62, 854-858.	1.5	13
47	Pre-Morbid Developmental Vulnerabilities in Children With Newly Diagnosed Acute Lymphoblastic Leukemia (ALL). <i>Pediatric Blood and Cancer</i> , 2015, 62, 2183-2188.	1.5	6
48	Transient myeloproliferative disorder in neonates without Down syndrome: case report and review. <i>European Journal of Haematology</i> , 2015, 94, 456-462.	2.2	14
49	The genomic landscape of juvenile myelomonocytic leukemia. <i>Nature Genetics</i> , 2015, 47, 1326-1333.	21.4	233
50	The Outcome of Allogeneic Hematopoietic Cell Transplantation for Children with FMS-Like Tyrosine Kinase 3 Internal Tandem Duplication-Positive Acute Myelogenous Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 172-175.	2.0	11
51	Treatment-Related Mortality (TRM) in Children with Down Syndrome (DS) and B-Lymphoblastic Leukemia (B-ALL): An Interim Report from the Children's Oncology Group Trials AALL0932 and AALL1131. <i>Blood</i> , 2015, 126, 2502-2502.	1.4	8
52	Predictors of Early Death in Childhood Acute Promyelocytic Leukemia: Results of an International Retrospective Study. <i>Blood</i> , 2015, 126, 172-172.	1.4	1
53	Neurocognitive Late Effects of Chemotherapy in Survivors of Acute Lymphoblastic Leukemia: Focus on Methotrexate. <i>Journal of the Canadian Academy of Child and Adolescent Psychiatry</i> , 2015, 24, 25-32.	0.6	28
54	Therapeutic Potential of Spleen Tyrosine Kinase Inhibition for Treating High-Risk Precursor B Cell Acute Lymphoblastic Leukemia. <i>Science Translational Medicine</i> , 2014, 6, 236ra62.	12.4	30

#	ARTICLE	IF	CITATIONS
55	Assessment of the Outcomes Associated with Periprocedural Anticoagulation Management in Children with Acute Lymphoblastic Leukemia. <i>Journal of Pediatrics</i> , 2014, 164, 1201-1207.	1.8	7
56	Leukapheresis and low-dose chemotherapy do not reduce early mortality in acute myeloid leukemia hyperleukocytosis: A systematic review and meta-analysis. <i>Leukemia Research</i> , 2014, 38, 460-468.	0.8	113
57	Risk of late effects of treatment in children newly diagnosed with standard-risk acute lymphoblastic leukaemia: a report from the Childhood Cancer Survivor Study cohort. <i>Lancet Oncology</i> , The, 2014, 15, 841-851.	10.7	108
58	Outcome of transplantation for acute lymphoblastic leukemia in children with down syndrome. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1126-1128.	1.5	24
59	Improvement in Treatment Outcome and Identification of a New Prognostic Parameter in Down Syndrome Acute Myeloid Leukemia (DS-AML): Results of the Children's Oncology Group (COG) Phase III AAML0431 Trial. <i>Blood</i> , 2014, 124, 278-278.	1.4	6
60	Differences of Somatic Mutations and Gene Expression in Blasts of Transient Leukemia and Acute Myeloid Leukemia of Down Syndrome. <i>Blood</i> , 2014, 124, 2364-2364.	1.4	0
61	Infections in children with down syndrome and acute myeloid leukemia: a report from the Canadian infections in AML research group. <i>Infectious Agents and Cancer</i> , 2013, 8, 47.	2.6	6
62	Outcome of Transplantation for Acute Myelogenous Leukemia in Children with Down Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 893-897.	2.0	39
63	Outcomes of treatment for relapsed acute lymphoblastic leukaemia in children with down syndrome. <i>British Journal of Haematology</i> , 2013, 162, 98-106.	2.5	28
64	Early Mortality In Hyperleukocytosis In Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis. <i>Blood</i> , 2013, 122, 2647-2647.	1.4	3
65	Estimated long-term outcomes in children newly diagnosed with standard risk acute lymphoblastic leukemia (ALL) based on similarly treated members of the childhood cancer survivor study (CCSS) cohort.. <i>Journal of Clinical Oncology</i> , 2013, 31, 10032-10032.	1.6	0
66	The Outcome Of Allogeneic Hematopoietic Cell Transplantation In Children With FLT3/ITD-Positive Acute Myelogenous Leukemia. <i>Blood</i> , 2013, 122, 2163-2163.	1.4	0
67	Transient Leukemia in Newborns Without Down Syndrome. <i>Journal of Pediatric Hematology/Oncology</i> , 2011, 33, e261-e263.	0.6	8
68	Conventional Reinduction/Consolidation-Type Therapy Versus Short Course High Intensity Combination Chemotherapy As Post-Induction Treatment for Children with Relapsed Acute Lymphoblastic Leukemia. Early Results of Study ALL-REZ BFM 2002. <i>Blood</i> , 2011, 118, 871-871.	1.4	5
69	GATA1 mutations Outside the Blast Cell Population in Transient Leukemia of Down Syndrome. <i>Blood</i> , 2011, 118, 2562-2562.	1.4	0
70	Cancer among Persons with Down Syndrome. <i>International Review of Research in Mental Retardation</i> , 2010, , 128-164.	0.7	0
71	Acute Leukemias in Children with Down Syndrome. <i>Hematology/Oncology Clinics of North America</i> , 2010, 24, 19-34.	2.2	35
72	Outcome and toxicity of chemotherapy for acute lymphoblastic leukemia in children with down syndrome. <i>Pediatric Blood and Cancer</i> , 2009, 52, 14-19.	1.5	34

#	ARTICLE	IF	CITATIONS
73	Lumbar spinal fluid collections in children treated with intrathecal chemotherapy: Elevated CSF protein as a diagnostic clue. <i>Pediatric Blood and Cancer</i> , 2008, 51, 295-298.	1.5	3
74	Acute Leukemias in Children with Down Syndrome. <i>Pediatric Clinics of North America</i> , 2008, 55, 53-70.	1.8	49
75	Acute megakaryoblastic leukemia in Down syndrome. <i>Pediatric Blood and Cancer</i> , 2007, 49, 1066-1069.	1.5	27
76	Use of recombinant factor VIIa prior to lumbar puncture in pediatric patients with acute leukemia. <i>Pediatric Blood and Cancer</i> , 2006, 47, 206-209.	1.5	10
77	Long-term results of an ultra low-dose cytarabine-based regimen for the treatment of acute megakaryoblastic leukaemia in children with Down syndrome. <i>British Journal of Haematology</i> , 2006, 133, 646-648.	2.5	54
78	Comparison of Long-Term Neurocognitive Outcomes in Young Children With Acute Lymphoblastic Leukemia Treated With Cranial Radiation or High-Dose or Very High-Dose Intravenous Methotrexate. <i>Journal of Clinical Oncology</i> , 2006, 24, 3858-3864.	1.6	159
79	Origins of leukaemia in children with Down syndrome. <i>Nature Reviews Cancer</i> , 2005, 5, 11-20.	28.4	192
80	Secondary Cytogenetic Abnormalities and Outcome in Children with TEL-AML1-Positive Acute Lymphoblastic Leukemia.. <i>Blood</i> , 2005, 106, 1450-1450.	1.4	1
81	Important Role of Routine Cerebrospinal Fluid Examination in Diagnosing Central Nervous System Relapse during Maintenance Therapy in Pediatric Acute Lymphoblastic Leukemia.. <i>Blood</i> , 2005, 106, 870-870.	1.4	1
82	CNS-directed therapy in young children with T-lineage acute lymphoblastic leukemia: High-dose methotrexate versus cranial irradiation. <i>Pediatric Blood and Cancer</i> , 2004, 42, 24-29.	1.5	15
83	GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome. <i>Blood</i> , 2003, 101, 4301-4304.	1.4	291
84	GATA1 – A Player in Normal and Leukemic Megakaryopoiesis. <i>Pediatric Research</i> , 2002, 52, 831-831.	2.3	3
85	Fusion of two novel genes, RBM15 and MKL1, in the t(1;22)(p13;q13) of acute megakaryoblastic leukemia. <i>Nature Genetics</i> , 2001, 28, 220-221.	21.4	268
86	Juvenile Chronic Myelogenous Leukemia Multilineage CD34+Cells: Aberrant Growth and Differentiation Properties. <i>Stem Cells</i> , 1996, 14, 690-701.	3.2	13